Group II metabotropic glutamate receptors and schizophrenia.

Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell (2011) 2.55

Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes. Pharmacol Rev (2010) 1.89

HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci (2012) 1.52

Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci Lett (2011) 1.21

Fractionation of spatial memory in GRM2/3 (mGlu2/mGlu3) double knockout mice reveals a role for group II metabotropic glutamate receptors at the interface between arousal and cognition. Neuropsychopharmacology (2011) 0.94

Prenatal stress induces schizophrenia-like alterations of serotonin 2A and metabotropic glutamate 2 receptors in the adult offspring: role of maternal immune system. J Neurosci (2013) 0.92

Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia. Sci Signal (2016) 0.84

Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics. CNS Neurol Disord Drug Targets (2010) 0.84

Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment. Trends Neurosci (2015) 0.80

G protein-coupled receptor heterocomplexes in neuropsychiatric disorders. Prog Mol Biol Transl Sci (2013) 0.80

Activation of metabotropic glutamate 2/3 receptors attenuates methamphetamine-induced hyperlocomotion and increase in prefrontal serotonergic neurotransmission. Psychopharmacology (Berl) (2011) 0.79

Manganese-enhanced magnetic resonance imaging reveals increased DOI-induced brain activity in a mouse model of schizophrenia. Proc Natl Acad Sci U S A (2014) 0.78

Epigenetic Mechanisms of Serotonin Signaling. ACS Chem Neurosci (2015) 0.77

ΔFosB induction in prefrontal cortex by antipsychotic drugs is associated with negative behavioral outcomes. Neuropsychopharmacology (2013) 0.77

Developmental decline in modulation of glutamatergic synapses in layer IV of the barrel cortex by group II metabotropic glutamate receptors. Neuroscience (2015) 0.77

HDAC2 as a new target to improve schizophrenia treatment. Expert Rev Neurother (2013) 0.76

The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia. Sci Rep (2016) 0.76

Epigenetic signaling in schizophrenia. Cell Signal (2015) 0.76

Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs. Front Pharmacol (2016) 0.75

Elucidation of molecular kinetic schemes from macroscopic traces using system identification. PLoS Comput Biol (2017) 0.75

Systematic protein-protein interaction mapping for clinically relevant human GPCRs. Mol Syst Biol (2017) 0.75

Metabotropic glutamate receptor 3 (mGlu3; mGluR3; GRM3) in schizophrenia: Antibody characterisation and a semi-quantitative western blot study. Schizophr Res (2016) 0.75

Meta-analysis supports GWAS-implicated link between GRM3 and schizophrenia risk. Transl Psychiatry (2017) 0.75

Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature (2008) 20.31

A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science (2006) 15.18

Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry (2003) 10.44

Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol (1997) 10.26

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry (2005) 9.23

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med (2007) 7.24

Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov (2009) 6.69

Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature (2000) 6.58

A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc Natl Acad Sci U S A (2007) 6.04

Chlorpromazine; new inhibiting agent for psychomotor excitement and manic states. AMA Arch Neurol Psychiatry (1954) 4.12

Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature (2008) 4.09

Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry (2002) 4.03

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry (2005) 3.74

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science (1998) 3.70

Neurobiology of schizophrenia. Neuron (2006) 3.69

Schizophrenia. N Engl J Med (2003) 3.65

Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol Ther (2003) 3.36

International Union of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol Rev (2005) 3.33

Roles of G-protein-coupled receptor dimerization. EMBO Rep (2004) 3.33

Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci (2008) 3.22

Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res (2008) 3.12

Transducin activation by nanoscale lipid bilayers containing one and two rhodopsins. J Biol Chem (2007) 3.07

Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet (2005) 3.03

Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21. Nat Genet (1998) 3.00

Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron (2007) 2.98

Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization. Nat Methods (2008) 2.88

Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd3+. Proc Natl Acad Sci U S A (2002) 2.75

International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev (2007) 2.62

Closed state of both binding domains of homodimeric mGlu receptors is required for full activity. Nat Struct Mol Biol (2004) 2.58

Psychiatric genetics: progress amid controversy. Nat Rev Genet (2008) 2.51

Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol Ther (2004) 2.44

Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci U S A (2004) 2.36

Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function. EMBO J (2001) 2.28

An international two-stage genome-wide search for schizophrenia susceptibility genes. Nat Genet (1995) 2.26

Monomeric G-protein-coupled receptor as a functional unit. Biochemistry (2005) 2.25

Functional reconstitution of Beta2-adrenergic receptors utilizing self-assembling Nanodisc technology. Biotechniques (2006) 2.22

Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia patients. Am J Psychiatry (2008) 2.13

Monomeric G protein-coupled receptor rhodopsin in solution activates its G protein transducin at the diffusion limit. Proc Natl Acad Sci U S A (2007) 2.07

MRNA stability and the control of gene expression: implications for human disease. Neurochem Res (2002) 1.94

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry (2007) 1.93

Metabotropic glutamate receptors. Cell Tissue Res (2006) 1.89

Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry (2006) 1.79

Genome-wide scan for schizophrenia in the Finnish population: evidence for a locus on chromosome 7q22. Hum Mol Genet (2000) 1.77

G protein-coupled receptor dimerisation: molecular basis and relevance to function. Biochim Biophys Acta (2006) 1.76

Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci (2008) 1.75

Are some cases of psychosis caused by microbial agents? A review of the evidence. Mol Psychiatry (2008) 1.74

NMDA receptors and schizophrenia. Curr Opin Pharmacol (2006) 1.73

Genome scan of European-American schizophrenia pedigrees: results of the NIMH Genetics Initiative and Millennium Consortium. Am J Med Genet (1998) 1.72

Adverse effects of atypical antipsychotics : differential risk and clinical implications. CNS Drugs (2007) 1.71

Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci (2003) 1.64

The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis. Biol Psychiatry (2004) 1.63

Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry (2003) 1.62

Activation of a dimeric metabotropic glutamate receptor by intersubunit rearrangement. J Biol Chem (2007) 1.57

Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther (2008) 1.55

Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. Proc Natl Acad Sci U S A (2007) 1.53

Molecular mechanisms of schizophrenia. Cell Physiol Biochem (2007) 1.53

Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk. Mol Psychiatry (2008) 1.51

Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev (2008) 1.46

Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull (2007) 1.45

Gene-environment interaction and covariation in schizophrenia: the role of obstetric complications. Schizophr Bull (2008) 1.44

A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther (2005) 1.43

A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol Pharmacol (2007) 1.42

Phenotype of schizophrenia: a review and formulation. Mol Psychiatry (2005) 1.41

Functional and structural characterization of rhodopsin oligomers. J Biol Chem (2006) 1.39

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) (2004) 1.38

The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl) (2007) 1.36

Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse (2005) 1.35

Activation mechanism of the heterodimeric GABA(B) receptor. Biochem Pharmacol (2004) 1.34

The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol (2008) 1.32

Psychedelics and schizophrenia. Trends Neurosci (2009) 1.32

Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc Natl Acad Sci U S A (2002) 1.30

Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia. Hum Genet (2006) 1.29

Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet (2003) 1.29

Pharmacological insights obtained from structure-function studies of ionotropic glutamate receptors. Br J Pharmacol (2006) 1.29

Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med (2001) 1.25

Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. Am J Med Genet (2002) 1.25

Replication of linkage on chromosome 7q22 and association of the regional Reelin gene with working memory in schizophrenia families. Mol Psychiatry (2007) 1.24

Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. J Neurochem (2009) 1.23

The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry (2007) 1.22

A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population. Schizophr Res (2005) 1.17

Linkage and associated studies of schizophrenia. Am J Med Genet (2000) 1.16

Expanding the 'central dogma': the regulatory role of nonprotein coding genes and implications for the genetic liability to schizophrenia. Mol Psychiatry (2005) 1.15

Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology (2000) 1.14

Latent effects of prenatal malnutrition on adult health: the example of schizophrenia. Ann N Y Acad Sci (2008) 1.14

Metabotropic glutamate 2/3 receptors as drug targets. Curr Opin Pharmacol (2004) 1.11

Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry (2006) 1.10

Heterodimerization of calcium sensing receptors with metabotropic glutamate receptors in neurons. J Biol Chem (2001) 1.06

gamma-aminobutyric acid(B) receptors: first of the functional metabotropic heterodimers. J Pharmacol Exp Ther (2000) 1.05

Expression of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP. Neuropsychopharmacology (2008) 1.05

The haloperidol story. Ann Clin Psychiatry (2006) 1.03

Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res (2005) 1.03

7TM receptors: the splicing on the cake. Trends Pharmacol Sci (1999) 1.03

Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: reversal by antipsychotic drugs. J Pharmacol Exp Ther (2006) 1.02

Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res Mol Brain Res (1998) 1.02

Effect of metabotropic glutamate receptor 3 genotype on N-acetylaspartate measures in the dorsolateral prefrontal cortex. Am J Psychiatry (2006) 1.00

Agonist-trafficking and hallucinogens. Curr Med Chem (2009) 1.00

Further evidence for a functional role of the glutamate receptor gene GRM3 in schizophrenia. Eur Neuropsychopharmacol (2008) 0.99

Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia. Biol Psychiatry (2007) 0.98

Schizophrenia: neural mechanisms for novel therapies. Mol Med (2003) 0.98

Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? Am J Psychiatry (2009) 0.98

Accuracy and calibration of commercial oligonucleotide and custom cDNA microarrays. Nucleic Acids Res (2002) 6.70

Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature (2008) 4.09

Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron (2007) 2.98

Influenza virus evades innate and adaptive immunity via the NS1 protein. J Virol (2006) 2.94

Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell (2011) 2.55

Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science (2006) 2.49

Local protein synthesis mediates a rapid increase in dendritic elongation factor 1A after induction of late long-term potentiation. J Neurosci (2005) 2.00

Focused microarray analysis. Methods (2003) 1.73

Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci (2003) 1.64

flowPeaks: a fast unsupervised clustering for flow cytometry data via K-means and density peak finding. Bioinformatics (2012) 1.53

HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci (2012) 1.52

Differential gene expression in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2011) 1.48

Monitoring G-protein-coupled receptor signaling with DNA microarrays and real-time polymerase chain reaction. Methods Enzymol (2002) 1.41

Chromosome-specific and noisy IFNB1 transcription in individual virus-infected human primary dendritic cells. Nucleic Acids Res (2007) 1.40

Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT₂A and mGlu₂ receptors in the adult offspring. J Neurosci (2011) 1.36

Interferon-beta pretreatment of conventional and plasmacytoid human dendritic cells enhances their activation by influenza virus. PLoS Pathog (2008) 1.32

Psychedelics and schizophrenia. Trends Neurosci (2009) 1.32

CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. Brain (2005) 1.30

Early single cell bifurcation of pro- and antiapoptotic states during oxidative stress. J Biol Chem (2004) 1.24

Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci Lett (2011) 1.21

Agonist-specific transactivation of phosphoinositide 3-kinase signaling pathway mediated by the dopamine D2 receptor. J Biol Chem (2003) 1.18

Improved compensation in flow cytometry by multivariable optimization. Cytometry A (2011) 1.15

Getting started in biological pathway construction and analysis. PLoS Comput Biol (2008) 1.14

Misty Mountain clustering: application to fast unsupervised flow cytometry gating. BMC Bioinformatics (2010) 1.13

Chronic exposure to TNF-alpha increases airway mucus gene expression in vivo. J Allergy Clin Immunol (2005) 1.13

Method for multiplex cellular detection of mRNAs using quantum dot fluorescent in situ hybridization. Nucleic Acids Res (2005) 1.12

Biphasic effects of postnatal exposure to diethylhexylphthalate on the timing of puberty in male rats. J Androl (2007) 1.11

Antiviral response dictated by choreographed cascade of transcription factors. J Immunol (2010) 1.10

Multiple testing and its applications to microarrays. Stat Methods Med Res (2009) 1.10

Research resource: Gonadotropin-releasing hormone receptor-mediated signaling network in LbetaT2 cells: a pathway-based web-accessible knowledgebase. Mol Endocrinol (2010) 1.09

Conserved helix 7 tyrosine acts as a multistate conformational switch in the 5HT2C receptor. Identification of a novel "locked-on" phenotype and double revertant mutations. J Biol Chem (2002) 1.05

Mixed analog/digital gonadotrope biosynthetic response to gonadotropin-releasing hormone. J Biol Chem (2006) 1.04

Bone morphogenetic protein 2 and activin A synergistically stimulate follicle-stimulating hormone beta subunit transcription. J Mol Endocrinol (2007) 1.04

Animal models of serotonergic psychedelics. ACS Chem Neurosci (2012) 1.03

Cytokine response is determined by duration of receptor and signal transducers and activators of transcription 3 (STAT3) activation. J Biol Chem (2012) 1.03

Transcript profiling of immediate early genes reveals a unique role for activating transcription factor 3 in mediating activation of the glycoprotein hormone alpha-subunit promoter by gonadotropin-releasing hormone. Mol Endocrinol (2005) 1.02

Time and length scales of autocrine signals in three dimensions. Biophys J (2007) 1.01

Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A·mGlu2) receptor heteromerization and its psychoactive behavioral function. J Biol Chem (2012) 1.00

The human herpesvirus 8 chemokine receptor vGPCR triggers autonomous proliferation of endothelial cells. J Clin Invest (2006) 1.00

Role of cell-to-cell variability in activating a positive feedback antiviral response in human dendritic cells. PLoS One (2011) 1.00

Agonist-trafficking and hallucinogens. Curr Med Chem (2009) 1.00

Acute induction of gene expression in brain and liver by insulin-induced hypoglycemia. Diabetes (2005) 1.00

Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors. Neuropharmacology (2011) 0.99

p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J Biol Chem (2006) 0.99

Structure of the GnRH receptor-stimulated signaling network: insights from genomics. Front Neuroendocrinol (2003) 0.98

BioPP: a tool for web-publication of biological networks. BMC Bioinformatics (2007) 0.98

Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J (2003) 0.97

Coupling of GnRH concentration and the GnRH receptor-activated gene program. Mol Endocrinol (2002) 0.95

Involvement of histone demethylase LSD1 in short-time-scale gene expression changes during cell cycle progression in embryonic stem cells. Mol Cell Biol (2012) 0.94

Immune response modeling of interferon beta-pretreated influenza virus-infected human dendritic cells. Biophys J (2010) 0.93

Genomics view of gonadotrope signaling circuits. Trends Endocrinol Metab (2004) 0.93

Signaling network of dendritic cells in response to pathogens: a community-input supported knowledgebase. BMC Syst Biol (2010) 0.92

Prenatal stress induces schizophrenia-like alterations of serotonin 2A and metabotropic glutamate 2 receptors in the adult offspring: role of maternal immune system. J Neurosci (2013) 0.92

Validated genomic approach to study differentially expressed genes in complex tissues. Neurochem Res (2002) 0.91

Epsilon-sarcoglycan immunoreactivity and mRNA expression in mouse brain. J Comp Neurol (2005) 0.90

Reduced levels of serotonin 2A receptors underlie resistance of Egr3-deficient mice to locomotor suppression by clozapine. Neuropsychopharmacology (2012) 0.90

Mining microarrays for metabolic meaning: nutritional regulation of hypothalamic gene expression. Neurochem Res (2004) 0.89

Molecular basis of partial agonism: orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy. Mol Pharmacol (2003) 0.89

SOME STEP-DOWN PROCEDURES CONTROLLING THE FALSE DISCOVERY RATE UNDER DEPENDENCE. Stat Sin (2008) 0.89

The HIV antiretroviral drug efavirenz has LSD-like properties. Neuropsychopharmacology (2013) 0.88

Noise propagation and scaling in regulation of gonadotrope biosynthesis. Biophys J (2007) 0.87

Dysregulated 5-HT(2A) receptor binding in postmortem frontal cortex of schizophrenic subjects. Eur Neuropsychopharmacol (2012) 0.86

Microtranscriptome regulation by gonadotropin-releasing hormone. Mol Cell Endocrinol (2009) 0.86

Distribution of prolyl endopeptidase activities in rat and human brain. Neurochem Int (2002) 0.84

Plato's cave algorithm: inferring functional signaling networks from early gene expression shadows. PLoS Comput Biol (2010) 0.84

Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics. CNS Neurol Disord Drug Targets (2010) 0.84

Novel Nipah virus immune-antagonism strategy revealed by experimental and computational study. J Virol (2010) 0.84

Validation of efficient high-throughput plasmid and siRNA transfection of human monocyte-derived dendritic cells without cell maturation. J Immunol Methods (2010) 0.82

Reconstruction of regulatory networks through temporal enrichment profiling and its application to H1N1 influenza viral infection. BMC Bioinformatics (2013) 0.82

Characterization of a MAPK scaffolding protein logic gate in gonadotropes. Mol Endocrinol (2011) 0.82

α₂-Adrenoceptor functionality in postmortem frontal cortex of depressed suicide victims. Biol Psychiatry (2010) 0.82

Optimized protocol for efficient transfection of dendritic cells without cell maturation. J Vis Exp (2011) 0.82

Mouse dendritic cell (DC) influenza virus infectivity is much lower than that for human DCs and is hemagglutinin subtype dependent. J Virol (2012) 0.81

G proteins and autocrine signaling differentially regulate gonadotropin subunit expression in pituitary gonadotrope. J Biol Chem (2012) 0.81

Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice. Psychopharmacology (Berl) (2012) 0.81

Repressive epigenetic changes at the mGlu2 promoter in frontal cortex of 5-HT2A knockout mice. Mol Pharmacol (2013) 0.80

β-catenin regulates GnRH-induced FSHβ gene expression. Mol Endocrinol (2012) 0.80

G protein-coupled receptor heterocomplexes in neuropsychiatric disorders. Prog Mol Biol Transl Sci (2013) 0.80

Chronic treatment with LY341495 decreases 5-HT(2A) receptor binding and hallucinogenic effects of LSD in mice. Neurosci Lett (2013) 0.79

Preclinical models of antipsychotic drug action. Int J Neuropsychopharmacol (2013) 0.79

Strategies for mapping the binding site of the serotonin 5-HT2A receptor. Methods Enzymol (2002) 0.78

Receptor pair for schizophrenia. Pediatr Res (2008) 0.78

Multi-scale stochastic simulation of diffusion-coupled agents and its application to cell culture simulation. PLoS One (2011) 0.77

HDAC2 as a new target to improve schizophrenia treatment. Expert Rev Neurother (2013) 0.76

Optimized amplification and single-cell analysis identify GnRH-mediated activation of Rap1b in primary rat gonadotropes. Mol Cell Endocrinol (2011) 0.76

Homer1 alternative splicing is regulated by gonadotropin-releasing hormone and modulates gonadotropin gene expression. Mol Cell Biol (2014) 0.76

Computational approaches to understanding dendritic cell responses to influenza virus infection. Immunol Res (2012) 0.75

Noise propagation through extracellular signaling leads to fluctuations in gene expression. BMC Syst Biol (2013) 0.75